Human Immunodeficiency Virus Clinical Trial
Official title:
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Verified date | June 4, 2021 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: - Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection. Most people do not have any symptoms when they become infected and are able to get rid of the infection on their own. However, they can still become re-infected with the same or a different HPV type, and in some people HPV infection persists. - Persistent HPV infection is associated with the development of precancerous lesions and cancer. HPV types are classified as either high risk or low risk based on whether their persistence will lead to cancer. - Patients who have suppressed immune systems are at a higher risk for HPV-related complications. They are more likely to contract multiple HPV types and have more persistent infection that can lead to precancerous lesions or cancer, which are then difficult to treat and often recur. - A recently approved vaccine for HPV induces immunity to HPV 6, 11, 16, and 18. It was shown to be highly effective in preventing infection with these HPV types, and is approved for use in females 9 to 26 years of age. However, much less is known about the vaccine s ability to induce immunity in males or individuals with suppressed immune systems. Objectives: - To investigate whether the HPV vaccine is safe to give and able to induce immunity in both female and male adolescents and young adults with HIV infection compared to healthy, HIV-negative persons of the same age. Eligibility: - Males and females, 12 to 26 years of age, divided into three groups: (1) Healthy and HIV-negative, (2) HIV-positive and on antiretroviral therapy, and (3) HIV-positive and not on antiretroviral therapy. Design: - Before beginning vaccination, participants will have a complete physical examination and blood drawn for routine blood tests, special tests of the immune system, antibody tests, and an HIV test. - HPV vaccine will be given by injection into the muscle at 0, 2, and 6 months, according to the standard vaccination schedule. - Patients with HIV infection will be monitored for a week following the first injection to test the level of HIV in the blood 3 days and 5 days after the first injection. - Participants will also be asked to fill out a 10- to 15-minute Web-based survey about awareness, health behaviors, and personal choices related to risk factors for HIV, HPV, and other sexually transmitted diseases. Participants are not required to fill out the survey to receive the vaccine. - The total duration of the study is 4 years. During the first year of the study, participants will return for six additional 1-day visits at months 1, 2, 3, 6, 7, and 12. Participants will return for 1-day visits every 6 months for the remaining 3 years.
Status | Completed |
Enrollment | 26 |
Est. completion date | February 4, 2013 |
Est. primary completion date | September 22, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 26 Years |
Eligibility | - ELIGIBILITY CRITERIA: Cohort 1 Inclusion and Exclusion Eligibility Criteria: INCLUSION CRITERIA: 2.1.1.1 Age 12 to 26 years 2.1.1.2 Females and males 2.1.1.3 HIV-positive 2.1.1.4 CD4 cell count and HIV-1 RNA level parameters - CD4 cell count greater than or equal to 350 cells/mm(3) - HIV-1 RNA level by RT PCR less than or equal to 20,000 copies/ml 2.1.1.5 On stable HAART regimen for greater than or equal to 6 months with CD4 and viral load parameters as outlined in 2.1.1.4 2.1.1.6 Patients greater than or equal to 18 years willing to provide informed consent or parent/guardian willing to provide informed consent for minor children less than 18 years of age. 2.1.1.7 Informed assent for patients 12-17 years of age (Optional at the discretion of the Principal Investigator and Parent/Guardian based on maturity level of minor) 2.1.1.8 Willing to use acceptable forms of contraception, if applicable, or abstinence to prevent pregnancy. EXCLUSION CRITERIA: 2.1.1.9 Any of the following hematologic abnormalities - Hemoglobin less than 10.0 g/dL - Neutrophil count less than 1500/mm(3) - Platelet count less than 75,000/mm(3) - PT or PTT greater than or equal to 1.5 times ULN (with the exception of patients with known clotting disorders or known lupus anticoagulant). 2.1.1.10 Any of the following hepatic abnormalities - ALT/SGPT and/or AST/SGOT greater than 2.5 times ULN - Total bilirubin greater than 1.5 times ULN unless attributable to protease inhibitor therapy. 2.1.1.11 Positive tests (antibody and/or antigen) for hepatitis B and hepatitis C viruses, unless the result is consistent with prior vaccination or prior infection with full recovery. 2.1.1.12 Acute infection requiring therapy at time of enrollment. Participants may be eligible for study after being on stable and appropriate anti-infective therapy. 2.1.1.13 Chemotherapy for active cancer. 2.1.1.14 Documented history of non-adherence to antiretroviral treatment regimen within 12 months of study entry. 2.1.1.15 Pregnancy or breastfeeding. 2.1.1.16 Use of immunosuppressive or immunomodulating agents within 8 weeks of study enrollment. Note: patients receiving oral corticosteroids for management of asthma or contact hypersensitivity for less than or equal to 14 days in duration will be allowed to enroll as long as it has been greater than or equal to 30 days since oral corticosteroid administration. 2.1.1.17 Known immediate hypersensitivity to yeast or any of the vaccine components. 2.1.1.18 Use of investigational agents within 4 weeks prior to study enrollment. 2.1.1.19 Active external genital warts requiring treatment or CIN2/3 2.1.1.20 Any clinically significant diseases (other than HIV infection) or findings during study screening that, in the opinion of the Principal Investigator or Lead Associate Investigator, may interfere with the study. Cohort 2 Inclusion and Exclusion Eligibility Criteria: Inclusion Criteria 2.1.2.1 Age 12 to 26 years 2.1.2.2 Females and males 2.1.2.3 HIV-positive 2.1.2.4 CD4 cell count and HIV-1 RNA level parameters - CD4 cell count greater than or equal to 500 cells/mm(3) - HIV-1 RNA level by RT PCR less than or equal to 20,000 copies/ml. 2.1.2.5 Not receiving antiretroviral treatment with CD4 and viral load parameters as outlined in 2.1.2.4. 2.1.2.6 Patients greater than or equal to 18 years willing to provide informed consent or parent/guardian willing to provide informed consent for minor children less than 18 years of age. 2.1.2.7 Informed assent for patients 12-17 years of age (Optional at the discretion of the Principal Investigator and Parent/Guardian based on maturity level of minor) 2.1.2.8 Willing to use acceptable forms of contraception, if applicable, or abstinence to prevent pregnancy. EXCLUSION CRITERIA: 2.1.2.9 Any of the following hematologic abnormalities: - Hemoglobin less than 10.0 g/dL - Neutrophil count less than 1500/mm(3) - Platelet count less than 75,000/mm(3) - PT or PTT greater than or equal to 1.5 times ULN (with the exception of patients with known clotting disorders or known lupus anticoagulant). 2.1.2.10 Any of the following hepatic abnormalities - ALT/SGPT and/or AST/SGOT greater than 2.5 times ULN - Total bilirubin greater than 1.5 times ULN unless attributable to protease inhibitor therapy. 2.1.2.11 Positive tests (antibody and/or antigen) for hepatitis B and hepatitis C viruses, unless the result is consistent with prior vaccination or prior infection with full recovery. 2.1.2.12 Acute infection requiring therapy at time of enrollment. Participants may be eligible for study after being on stable and appropriate anti-infective therapy. 2.1.2.13 Chemotherapy for active cancer. 2.1.2.14 Pregnancy or breastfeeding. 2.1.2.15 Use of immunosuppressive or immunomodulating agents within 8 weeks prior to study enrollment. Note: patients receiving oral corticosteroids for management of asthma or contact hypersensitivity for less than or equal to 14 days in duration will be allowed to enroll as long as it has been greater than or equal to 30 days since oral corticosteroid administration. 2.1.2.16 Known immediate hypersensitivity to yeast or any of the vaccine components. 2.1.2.17 Use of investigational agents within 4 weeks prior to study enrollment. 2.1.2.18 Active external genital warts requiring treatment or CIN2/3 2.1.2.19 Any clinically significant diseases (other than HIV infection) or findings during study screening that, in the opinion of the Principal Investigator or Lead Associate Investigator may interfere with the study. Cohort 3 Inclusion and Exclusion Eligibility Criteria: INCLUSION CRITERIA: 2.1.3.1 Age 12 to 26 years 2.1.3.2 Females and males 2.1.3.3 HIV-negative 2.1.3.4 Patients greater than or equal to 18 years willing to provide informed consent or parent/guardian willing to provide informed consent for minor children less than 18 years of age. 2.1.3.5 Informed assent for patients 12-17 years of age (Optional at the discretion of the Principal Investigator and Parent/Guardian based on maturity level of minor) 2.1.3.6 Willing to use acceptable forms of contraception, if applicable, or abstinence to prevent pregnancy. EXCLUSION CRITERIA: 2.1.3.7 Any of the following hematologic abnormalities: - Hemoglobin less than 10.0 g/dL - Neutrophil count less than 1500/mm(3) - Platelet count less than 75,000/mm(3) - PT or PTT greater than or equal to 1.5 times ULN (with the exception of patients with known clotting disorders or known lupus anticoagulant). 2.1.3.8 Any of the following hepatic abnormalities - ALT/SGPT and/or AST/SGOT greater than 2.5 times ULN - Total Bilirubin greater than 1.5 times ULN unless attributable to protease inhibitor therapy. 2.1.3.9 Positive tests (antibody and/or antigen) for HIV, hepatitis B and hepatitis C viruses, unless the result is consistent with prior vaccination or prior infection with full recovery. 2.1.3.10 Acute infection requiring therapy at time of enrollment. Participants may be eligible for study after being on stable and appropriate anti-infective therapy. 2.1.3.11 Chemotherapy for active cancer. 2.1.3.12 Pregnancy or breastfeeding 2.1.3.13 Use of immunosuppressive or immunomodulating agents within 8 weeks prior to study enrollment. Note: patients receiving oral corticosteroids for management of asthma or contact hypersensitivity for less than or equal to 14 days in duration will be allowed to enroll as long as it has been greater than or equal to 30 days since oral corticosteroid administration. 2.1.3.14 Known immediate hypersensitivity to yeast or any of the vaccine components. 2.1.3.15 Use of investigational agents within 4 weeks prior to study enrollment. 2.1.3.16 Active external genital warts requiring treatment or CIN2/3 2.1.3.17 Any clinically significant diseases or findings during study screening that, in the opinion of the Principal Investigator or Lead Associate Investigator may interfere with the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004 Dec;31(12):748-52. — View Citation
Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-63. Review. — View Citation
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the immunogenicity and safety of the quadrivalent human papillomavirus recombinant vaccine in HIV- infected preadolescents, adolescents and young adults 12-26 years of age | Assessment of adverse events, their characteristics, duration and quantity for the entire study population. | screening and months 1, 2, 3, 6, 7, 12, 18, 24, 30, 36, 42 and 48 post first vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |